Transcript SWAG Research Breast SSG 27012017

Clinical Research Network
West of England
SWAG SSG Breast Cancer Meeting
Friday 27th January 2017
Research Report
Clinical Research Network & Cancer Services
West ofEngland
SWAG - Somerset Wiltsire Avon & Gloucestershire
South West Children’s Cancer & Leukaemia
Research Network
NIHR CRN High Level Objectives
• Increase number of participants into NIHR CRN portfolio studies
• 650,000 in England
• 21,905 in West of England
• Increase the number of studies that deliver to time and target
• Target 80%
• Increase number of commercial studies delivered through network
• Reduce NHS study set up times
• Reduce time taken to recruit first participant
NIHR CRN Objectives for cancer
• Recruit 20% of cancer incidence
• West of England 1,909
• Recruit 7.5% of cancer incidence into interventional studies
• 716
• Include challenging studies
•
•
•
•
•
Cancer surgery – 4 recruits per 100,000 population
Radiotherapy – 6 recruits per 100,000 population
Rare cancers (<6 per 100,000) – 12 recruits per 100,000 population
Children & young people – 3 per 100,000 population
Teenagers & young adults – record number of 16-25 year olds participating in
research
*Please note the Office of National Statistics uses different regions from the NIHR so this calculation is approximate. The
South West region loosely correlates to West of England and South West Peninsula CRNs, with the addition of Dorset.
West of England recruitment to Cancer studies per Trust
What does the current portfolio look like?
• 23 Studies
• 8 Acute Trusts in the SWAG region.
• 72% of study sites are currently meeting Recruitment to Time and
Target (RTT)
• POSNOC in Bath
• M12-914 Phase III Veliparib/ Placebo + C/P Breast Cancer Study in University
Hospitals Bristol
• Breast cancer studies open in SWAG largely reflect a balanced
portfolio by sub-topic, though only 1 metastatic study is open at
present
Current portfolio balance
Studies in set up – Breast Cancer
Portfolio
ID
Study Title
CiPHER - Cabazitaxel in Patients with HER2-negative
metastatic breast cancer and having unresectable brain
16444 metastases
IBIS 3: POLaR - Prevention Of Late Recurrence in ER+
breast cancer survivors following 5 years of adjuvant
19708 treatment
19754 Exercise to prevent shoulder problems (PROSPER)
Project type
Trust
Non-commercial
University Hospitals Bristol Bahl, Dr Amit
Non-commercial
Non-commercial
University Hospitals Bristol
University Hospitals Bristol
PARTNER - addition of olaparib to platinum-based
neoadjuvant chemotherapy in breast cancer patients with
Non-commercial
30433 TNBC and/or gBRCA
CompLEEment-1 - ribociclib (LEE011) in combination with
letrozole for the treatment of men and postmenopausal
women with hormone receptor-positive (HR+) HER2Commercial
31440 negative (HER2-) advanced breast cancer
plasmaMATCH - The UK plasma based Molecular profiling
31608 of Advanced breast cancer to inform Therapeutic Choices Non-commercial
PALLAS - Palbociclib with standard adjuvant endocrine
therapy versus standard adjuvant endocrine therapy
Non-commercial
32994 alone for HR+ / HER2 - early breast cancer
Principal Investigator
University Hospitals Bristol Braybrooke, Dr Jeremy
University Hospitals Bristol
University Hospitals Bristol Braybrooke, Dr Jeremy
University Hospitals Bristol Braybrooke, Dr Jeremy
Current issues with breast cancer research
• Clinical pressures with some trial treatments
• Pharmacy capacity issues
• Extra time for administration of infusions
• Extra length of treatment courses
• Clinic space to see patients
• Affordability to the NHS of the drugs we are researching
• What should our regional portfolio look like?
• Should we consider the whole region population when forecasting for trials?
• Should we encourage more cross referral of patients for studies?
• Should we select studies that will be more useful to the NHS?
Useful links
• https://www.crn.nihr.ac.uk/
• National and local network information including training programmes templates,
tools, contacts, videos etc
• https://odp.nihr.ac.uk/ http:/
• Open data platform. Look at performance across whole CRN including all specialty
areas
• /csg.ncri.org.uk/portfolio/portfolio-maps/
• View current national portfolio of open, closed and ‘in set up’ cancer studies
• https://www.ukctg.nihr.ac.uk/
• See where a study is open across the country
• http://public-odp.nihr.ac.uk/
• Search for a study to fit criteria. Good for horizon scanning, eligibility criteria
Contacts
• Research Delivery Manager – [email protected]
• Cancer portfolio facilitator – [email protected]
• Breast cancer research lead – [email protected]